Moleculin Biotech, Inc.
MBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $18 | $19 | $19 | $14 |
| G&A Expenses | $9 | $10 | $12 | $8 |
| SG&A Expenses | $9 | $10 | $12 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $27 | $30 | $31 | $23 |
| Operating Income | -$27 | -$30 | -$31 | -$23 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | -$0 | $2 | $7 |
| Pre-Tax Income | -$22 | -$30 | -$29 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$22 | -$30 | -$29 | -$16 |
| % Margin | – | – | – | – |
| EPS | -158 | -376.75 | -380.5 | -221.75 |
| % Growth | 58.1% | 1% | -71.6% | – |
| EPS Diluted | -158 | -376.75 | -380.5 | -221.75 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$27 | -$30 | -$31 | -$23 |
| % Margin | – | – | – | – |